AstraZeneca: acquires Belgian biotech firm EsoBiotec
(CercleFinance.com) - AstraZeneca announces that it has entered into a definitive agreement to acquire EsoBiotec, a biotechnology company pioneering in vivo cell therapies.
EsoBiotec's ENaBL (Engineered NanoBody Lentiviral) platform enables the immune system to fight cancers, and could offer more patients access to revolutionary cell therapy treatments administered in just minutes, as opposed to the current process which takes weeks.
We are delighted with the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform, AstraZeneca said.
EsoBiotec will become a wholly-owned subsidiary of AstraZeneca, operating in Belgium.
AstraZeneca will acquire all outstanding shares of EsoBiotec for a total consideration of up to $1bn. This amount will include an upfront payment of $425m at closing and a contingent amount of up to $575m, depending on development milestones and regulatory requirements.
Copyright (c) 2025 CercleFinance.com. All rights reserved.
EsoBiotec's ENaBL (Engineered NanoBody Lentiviral) platform enables the immune system to fight cancers, and could offer more patients access to revolutionary cell therapy treatments administered in just minutes, as opposed to the current process which takes weeks.
We are delighted with the acquisition of EsoBiotec and the opportunity to rapidly advance their promising in vivo platform, AstraZeneca said.
EsoBiotec will become a wholly-owned subsidiary of AstraZeneca, operating in Belgium.
AstraZeneca will acquire all outstanding shares of EsoBiotec for a total consideration of up to $1bn. This amount will include an upfront payment of $425m at closing and a contingent amount of up to $575m, depending on development milestones and regulatory requirements.
Copyright (c) 2025 CercleFinance.com. All rights reserved.